AZN vs SNAL · P/E 28, $288.38B cap vs rev $81.2M
AstraZeneca PLC (AZN) versus Snail, Inc. Class A Common Stock (SNAL) — a side-by-side from cached financials, not a winner call.
AstraZeneca PLC (AZN) is a drug manufacturers - general company listed on US.
Snail, Inc. Class A Common Stock (SNAL) is a electronic gaming & multimedia company listed on NASDAQ.
AZN does not have a complete income-statement cache yet.
Latest reported SNAL revenue for 2025-12-31 was $81.2M. Net income was -$27.2M. Revenue was down 3.8% from 2024-12-31 to 2025-12-31. SNAL currently screens at market cap $27.0M.
AZN currently screens at market cap $288.38B and trailing P/E 28.0. SNAL currently screens at market cap $27.0M.
Not investment advice. Open the AZN and SNAL stock pages for the full models.
Not investment advice.